Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (5): 264-267.
Previous Articles Next Articles
QIN Hai-yan,CHEN Li-juan,WU Xiao-li,ZHU Hong,ZHANG Yun,ZHU Hong-chao
Received:
2017-10-24
Revised:
2018-06-21
Online:
2018-05-20
Published:
2018-06-21
Contact:
朱蕻潮,男,硕士,住院医师,心血管疾病的基础及影像学。E-mail:zhuhongchao366@126.com
CLC Number:
QIN Hai-yan,CHEN Li-juan,WU Xiao-li,ZHU Hong,ZHANG Yun,ZHU Hong-chao. Analysis of Adverse Reactions on the Elevated Triglyceride Levels Caused by Tretinoin Tablets in Treatment of Patients with Psoriasis Vulgaris[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 264-267.
[1] 曲彤. 阿维A胶囊联合复方甘草酸苷片治疗寻常型银屑病40例疗效观察[J]. 山西职工医学院学报, 2012, 22(3):43-44. [2] 彭振辉, 牛新武. 维A酸类药物与皮肤病[J]. 中国皮肤性病学杂志, 2004,18(6):374-378. [3] 赵辨. 临床皮肤病学彩色图谱[M]. 南京:江苏科技出版社, 2001:750-762. [4] 王洁, 徐蓉, 李斌. 加味芩珠凉血方联合他扎罗汀凝胶治疗血热证寻常型银屑病的疗效观察[J]. 上海交通大学学报(医学版), 2016, 36(11):1610-1612. [5] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5):390-419. [6] 徐风花. 维A酸软膏对于皮肤病的治疗[J].现代养生(下半月版), 2016, (8):103. [7] 金红星. 单芳香维A酸类药物治疗寻常型银屑病效果观察[J]. 白求恩医学杂志, 2015, 13(1):41. [8] 堵建刚. 阿维A酸与甲氨蝶呤治疗寻常型重度银屑病效果比较[J]. 中国乡村医药, 2015, 22(15):17-18. [9] 陈卫丰, 胡伟才. 复方甘草酸苷注射液联合阿维A胶囊治疗红皮病性银屑病的疗效分析[J]. 临床研究, 2015, 4(12):158-159. [10] 周欣, 张锡宝. 维A酸在皮肤科临床应用的现状与进展[J].临床皮肤科杂志, 2011, 40(11):706-709. [11] 梁建梅. 维A酸类药物在皮肤科的临床应用[J]. 医药产业资讯, 2006, 3(12):153-154. [12] 王晓飞, 赵厌平, 陈燕玲. 口服维A酸类药物常见不良反应的观察及护理[J]. 中华护理杂志, 2005, 40(9):688-689. [13] Austin M A. Epidemiology of hypertriglyceridemia and cardiovascular disease[J]. Am J cardiol, 1999, 83(9):13-16. [14] M J, Stampfer,R M, Krauss,J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction[J]. JAMA, 1996, 276(11):882-888. [15] 石亮, 黄娜娜, 孙蓉. 血脂宁药理毒理学研究进展[J]. 中国药物警戒, 2016, 13(6):347-350. [16] Havel R J. The formation of LDL: mechanisms and regulation[J]. Journal of lipid research, 1984, 25(13):1570-1576. [17] LaRosa J C. Cholesterol management in women and the elderly[J]. Journal of internal medicine, 1997, 241(4):307-316. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||